This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Keilson, L. Articles by McLeod, J. F. Search for Related Content PubMed PubMed Citation Articles by Keilson, L. Articles by McLeod, J. F.

Synergistic Effects of Nateglinide and Meal Administration on Insulin Secretion in Patients with Type 2 Diabetes Mellitus

Clinical Research Management (L.K.), Portland, Maine 04102; Lee Coast Research Center (S.M.), Fort Myers, Florida 33901; and Novartis Pharmaceuticals Corp. (Y.H.W., S.S., J.F.M.), East Hanover, New Jersey 07936

Address all correspondence and requests for reprints to: James F. McLeod, M.D., Clinical Pharmacology, Novartis Pharmaceuticals Corp., 59 Route 10, East Hanover, New Jersey 07936. E-mail: james.mcleod{at}pharma.novartis.com

This study assessed the synergistic effects of nateglinide (a nonsulfonylurea D-phenylalanine derivative) and meals on insulin secretion in 24 patients with type 2 diabetes. Oral doses of 60 and 180 mg or 120 and 240 mg were administered to two cohorts of subjects 10 min before meals (or fasting) three times daily for 7 days, with washout intervals between treatment periods. Dose-dependent increases in plasma insulin occurred, with the peak effect within 2 h after treatment. Significantly greater insulin secretion was observed when nateglinide was taken before a meal compared to nateglinide given in the fasted state or in response to just the meal. Nateglinide lowered plasma glucose concentrations significantly vs. placebo at all doses, and doses of 120 and 240 mg were more effective than 60 mg (P < 0.05). Adverse event rates were similar for nateglinide and placebo, and no hypoglycemic episodes or serious adverse events were reported during the study. Nateglinide (120 mg) was the maximum effective dose in this study and was shown to be a safe and well tolerated therapy for control of mealtime glucose excursions in patients with type 2 diabetes. Results indicate that a synergistic interaction occurs between nateglinide and elevated mealtime plasma glucose concentrations to stimulate insulin secretion.

This article has been cited by other articles:

				H. A. Spiller and T. S. Sawyer Toxicology of oral antidiabetic medications Am. J. Health Syst. Pharm., May 15, 2006; 63(10): 929 - 938. [Abstract] [Full Text] [PDF]

				S. Del Prato, R. J. Heine, L. Keilson, C. Guitard, S. G. Shen, and R. P. Emmons Treatment of Patients Over 64 Years of Age With Type 2 Diabetes: Experience from nateglinide pooled database retrospective analysis Diabetes Care, July 1, 2003; 26(7): 2075 - 2080. [Abstract] [Full Text] [PDF]

				M. F. Carroll, A. Izard, K. Riboni, M. R. Burge, and D. S. Schade Control of Postprandial Hyperglycemia: Optimal use of short-acting insulin secretagogues Diabetes Care, December 1, 2002; 25(12): 2147 - 2152. [Abstract] [Full Text] [PDF]

				J. Rosenstock, S. G. Shen, M. R. Gatlin, and J. E. Foley Combination Therapy With Nateglinide and a Thiazolidinedione Improves Glycemic Control in Type 2 Diabetes Diabetes Care, September 1, 2002; 25(9): 1529 - 1533. [Abstract] [Full Text] [PDF]

				S. E. Inzucchi Oral Antihyperglycemic Therapy for Type 2 Diabetes: Scientific Review JAMA, January 16, 2002; 287(3): 360 - 372. [Abstract] [Full Text] [PDF]

				S. D. Luzio, D. M. Anderson, and D. R. Owens Effects of Timing of Administration and Meal Composition on the Pharmacokinetic and Pharmacodynamic Characteristics of the Short-Acting Oral Hypoglycemic Agent Nateglinide in Healthy Subjects J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4874 - 4880. [Abstract] [Full Text] [PDF]

				F. M. Gribble, S. E. Manley, and J. C. Levy Randomized Dose Ranging Study of the Reduction of Fasting and Postprandial Glucose in Type 2 Diabetes by Nateglinide (A-4166) Diabetes Care, July 1, 2001; 24(7): 1221 - 1225. [Abstract] [Full Text] [PDF]

				M. L. Weaver, B. A. Orwig, L. C. Rodriguez, E. D. Graham, J. A. Chin, M. J. Shapiro, J. F. McLeod, and J. B. Mangold Pharmacokinetics and Metabolism of Nateglinide in Humans Drug Metab. Dispos., April 1, 2001; 29(4): 415 - 421. [Abstract] [Full Text]

				J. B. Kalbag, Y. H. Walter, J. R. Nedelman, and J. F. McLeod Mealtime Glucose Regulation With Nateglinide in Healthy Volunteers: Comparison with repaglinide and placebo Diabetes Care, January 1, 2001; 24(1): 73 - 77. [Abstract] [Full Text]